Initial Study of Methylclonazepam in Generalized Anxiety Disorder. Evidence for Greater Power in the Cross-over Design

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1985 Jan 1

PMID 3931136

Citations 5

Authors

M Ansseau

A Doumont

D Thiry

R von Frenckell

J Collard

Affiliations

Soon will be listed here.

Abstract

The anxiolytic activity of methylclonazepam was compared to lorazepam and placebo in a double-blind, randomized cross-over study, using a latin square design, in 18 inpatients meeting Research Diagnostic Criteria for Generalized Anxiety Disorders. Patients presented at least 1 year of symptomatology and had a minimum score of 20 on the Hamilton Anxiety Scale, despite chronic anxiolytic pharmacotherapy. Daily dosage was flexible, from three to six tablets of methylclonazepam 1 mg, lorazepam 2.5 mg, or placebo. Clinical evaluation included Hamilton Anxiety Scale, Clinical Global Impression (CGI), a side-effects checklist, completed every 2 days, and the global preference of the patient for one of the treatment periods. Results showed a highly significant superiority of both benzodiazepines over placebo on the Hamilton Scale (P less than 0.000001) and CGI (P less than 0.001), and also a significant superiority of methylclonazepam over lorazepam on the Hamilton Scale (P less than 0.01), CGI-1 (P less than 0.01), and in the number of patient preferences (14 versus 1; P less than 0.001), with no significant differences in side-effects or related to position in the trial. These results support the value of the cross-over design in chronic and severe anxious inpatients for the demonstration of differences in efficacy between anxiolytic pharmacotherapies.

Citing Articles

Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Brunetti P, Giorgetti R, Tagliabracci A, Huestis M, Busardo F Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34208284 PMC: 8230725. DOI: 10.3390/ph14060560.

'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.

Orsolini L, Corkery J, Chiappini S, Guirguis A, Vento A, de Berardis D Curr Neuropharmacol. 2020; 18(9):809-837.

PMID: 31933443 PMC: 7569319. DOI: 10.2174/1570159X18666200110121333.

Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples.

Vikingsson S, Wohlfarth A, Andersson M, Green H, Roman M, Josefsson M AAPS J. 2017; 19(3):736-742.

PMID: 28091881 DOI: 10.1208/s12248-016-0040-x.

Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use.

Abdul-Ghani R, Loutfy N, Hassan A Parasitol Res. 2009; 105(4):899-906.

PMID: 19588166 DOI: 10.1007/s00436-009-1546-2.

Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder.

Ansseau M, Olie J, von Frenckell R, Jourdain G, Stehle B, Guillet P Psychopharmacology (Berl). 1991; 104(4):439-43.

PMID: 1685793 DOI: 10.1007/BF02245646.

References

Greenblatt D, Divoll M, Abernethy D, Ochs H, Shader R . Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev. 1983; 14(2):251-92. DOI: 10.3109/03602538308991391. View

Uhlenhuth E, Glass R, FISCHMAN M . Multiple crossover designs with an antianxiety agent and an antidepressant. Psychopharmacol Bull. 1979; 15(3):37-40. View

Spitzer R, Endicott J, Robins E . Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978; 35(6):773-82. DOI: 10.1001/archpsyc.1978.01770300115013. View

Aranko K, Mattila M, Seppala T . Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br J Clin Pharmacol. 1983; 15(5):545-52. PMC: 1427709. DOI: 10.1111/j.1365-2125.1983.tb02088.x. View

Solomon K, Hart R . Pitfalls and prospects in clinical research on antianxiety drugs: benzodiazepines and placebo--a research review. J Clin Psychiatry. 1978; 39(11):823-31. View

Ansseau M, Doumont A, von Frenckell R, Collard J . A long-acting benzodiazepine is more effective in divided doses. N Engl J Med. 1984; 310(8):526. DOI: 10.1056/NEJM198402233100813. View

Greenblatt D, Shader R, Abernethy D . Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983; 309(6):354-8. DOI: 10.1056/NEJM198308113090607. View

Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x. View

Ansseau M, Doumont A, von Frenckell R, Collard J . Duration of benzodiazepine clinical activity: lack of direct relationship with plasma half-life. A comparison of single vs divided dosage schedules of prazepam. Psychopharmacology (Berl). 1984; 84(3):293-8. DOI: 10.1007/BF00555201. View

10.

Hills M, Armitage P . The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979; 8(1):7-20. PMC: 1429717. DOI: 10.1111/j.1365-2125.1979.tb05903.x. View

11.

Rickels K, Lipman R, PARK L, Covi L, Uhlenhugh E, Mock J . Drug, doctor warmth, and clinic setting in the symptomatic response to minor tranquilizers. Psychopharmacologia. 1971; 20(2):128-52. DOI: 10.1007/BF00404367. View

12.

Goldberg H . Benzodiazepine and nonbenzodiazepine anxiolytics. Psychopathology. 1984; 17 Suppl 1:45-55. DOI: 10.1159/000284077. View

13.

Bellantuono C, Reggi V, Tognoni G, Garattini S . Benzodiazepines: clinical pharmacology and therapeutic use. Drugs. 1980; 19(3):195-219. DOI: 10.2165/00003495-198019030-00004. View

14.

SONNE L, Holm P . A comparison between bromazepam (Ro 5-3350, Lexotan) and diazepam (Valium) in anxiety neurosis. A controlled, double-blind clinical trial. Int Pharmacopsychiatry. 1975; 10(2):125-8. DOI: 10.1159/000468179. View

15.

Lapierre Y . Are all benzodiazepines clinically equivalent?. Prog Neuropsychopharmacol Biol Psychiatry. 1983; 7(4-6):641-6. DOI: 10.1016/0278-5846(83)90038-6. View

16.

Mellinger G, Balter M, Uhlenhuth E . Prevalence and correlates of the long-term regular use of anxiolytics. JAMA. 1984; 251(3):375-9. View

17.

Lader M, Petursson H . Rational use of anxiolytic/sedative drugs. Drugs. 1983; 25(5):514-28. DOI: 10.2165/00003495-198325050-00004. View

18.

Bobon J, Collard J, KERF J . [Tranquilizers and placebo: a "double blind" study]. Rev Med Liege. 1962; 17:9-14. View

19.

. Choice of a benzodiazepine for treatment of anxiety or insomnia. Med Lett Drugs Ther. 1977; 19(12):49-50. View

20.

KESSON C, Gray J, Lawson D . Benzodiazepine drugs in general medical patients. Br Med J. 1976; 1(6011):680-2. PMC: 1639128. DOI: 10.1136/bmj.1.6011.680. View